Gemina Laboratories Ltd.

As of April 30, 2025, Gemina Laboratories Ltd. has 76.57M shares outstanding.

These figures are as of April 30, 2025. The price-to-sales ratio is 6,946.42, and the price-to-book ratio stands at -8.56.

These figures are as of April 30, 2025. The EV/Sales ratio of 6,967.44 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of April 30, 2025, Gemina Laboratories Ltd. maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -5.54, indicating conservative leverage, while an interest coverage ratio of -21.97 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended April 30, 2025. Return on assets (ROA) is negative at -305.45, reflecting losses generated across the asset base.

Over the twelve months ended April 30, 2025, Gemina Laboratories Ltd. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -35,059.93 and net profit margin of -36,846.40 provide insight into operational efficiency.

These figures cover the twelve months ended April 30, 2025. Free cash flow yield is negative at -0.62: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.61, meaning Gemina Laboratories Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of April 30, 2025, Gemina Laboratories Ltd. has an Altman Z-Score of -33.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.